Clinical Trial Update: Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug [Phase 2]

View source ↗

Summary

Phase 2 trial update on BAY2976217 (Factor XI LICA) assessing safety, pharmacokinetics, and distribution in patients with end-stage renal disease on hemodialysi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Failure On Dialysis

Drugs mentioned

• BAY2976217 (BAY2976217)

Snippet

Sponsor: Bayer | Conditions: End Stage Renal Disease Requiring Hemodialysis | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03